Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides

scientific article

Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/AAC.31.9.1383
P932PMC publication ID174947
P698PubMed publication ID3674849
P5875ResearchGate publication ID19486784

P2093author name stringJ M Gatell
E Soriano
M Bonet
J Traserra
V Araujo
J G SanMiguel
F Ferran
P2860cites workControlled Comparison of Amikacin and GentamicinQ28324094
Relationship Between Aminoglycoside-Induced Nephrotoxicity and Auditory ToxicityQ28327774
Immediate effects of tobramycin on human cochlea and correlation with serum tobramycin levelsQ28330663
Ototoxicity of Tobramycin: A Clinical OverviewQ28336416
Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicinQ28366502
Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicityQ33727669
Comparative nephrotoxicities of high-dose netilmicin and tobramycin in ratsQ33732072
Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycinQ34056699
Aminoglycoside ototoxicity in the humanQ34057509
Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibuleQ35574233
Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacinQ35745224
Pharmacology and efficacy of netilmicinQ36469912
Netilmicin in Gram-Negative Bacterial InfectionsQ36477089
Amikacin serum concentrations: prediction of levels and dosage guidelinesQ39214222
Aminoglycoside antibiotics in infectious diseases. An overviewQ39738119
Age related changes influencing the effects of drugs and other xenobiotics on sensorineural hearingQ40203004
Comparison of Netilmicin and Amikacin in Treatment of Complicated Urinary Tract InfectionsQ40619286
Hyperthermia increases aminoglycoside ototoxicity.Q40837471
Comparative Toxicity of Netilmicin and Gentamicin in Squirrel Monkeys (Saimiri sciureus)Q41407938
Clinical evaluation of netilmicin therapy in serious infectionsQ41435773
Comparative ototoxic liability of netilmicin and gentamicinQ42111978
Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditisQ42248893
Effect of furosemide on aminoglycoside-induced nephrotoxicity and auditory toxicity in humansQ42928339
Combined effect of noise and neomycin on the cochleaQ46204029
Alteration of aminoglycoside antibiotic ototoxicity by hyper- and hypohydrationQ46205404
Have the new beta-lactams rendered the aminoglycosides obsolete for the treatment of serious nosocomial infections?Q50579005
Risk factors for the development of auditory toxicity in patients receiving aminoglycosides.Q50589543
Comparative clinical studies of ototoxicity and nephrotoxicity of amikacin and gentamicin.Q50622127
Alteration of aminoglycoside antibiotic ototoxicity: effect of semistarvation.Q53925219
Comparative nephrotoxicity of aminoglycoside antibiotics in ratsQ67404923
Empirical antimicrobial therapy in the neutropenic hostQ68891378
A model for predicting nephrotoxicity in patients treated with aminoglycosidesQ69493303
Tobramycin and amikacin nephrotoxicity. Value of serum creatinine versus urinary concentration of beta-2-microglobulinQ69919330
Micro-determination of tobramycin in serum by high-performance liquid chromatography with ultraviolet detectionQ70976303
Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicinQ72551535
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectmultivariate statisticsQ1952580
P304page(s)1383-7
P577publication date1987-09-01
P1433published inAntimicrobial Agents and ChemotherapyQ578004
P1476titleUnivariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides
P478volume31

Reverse relations

cites work (P2860)
Q28316869A comparison of netilmicin and tobramycin therapy in patients with renal impairment
Q40805018A population approach to the forecasting of amikacin plasma and urinary levels using a prescribed dosage regimen
Q48303892Adverse effects of a single dose of gentamicin in adults: a systematic review
Q40766816Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia
Q38919674Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review
Q40720366Aminoglycoside dosage regimens. Is once a day enough?
Q37941557Aminoglycoside therapy. Current use and future prospects
Q38676819Aminoglycoside-induced hearing loss in humans
Q37224123Aminoglycoside-induced vestibular injury: maintaining a sense of balance
Q43872720Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate?
Q90589972Analysis of drug-induced hearing loss by using a spontaneous reporting system database
Q38006505Antimicrobial therapy for the elderly patient
Q37060143Audiological Evaluation of Patients Taking Kanamycin for Multidrug Resistant Tuberculosis
Q95728061Audiometric threshold shifts after total knee arthroplasty by using gentamicin-loaded bone cement
Q43787795Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections
Q30240026Drug-induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies
Q40594113Experimental, clinical and preventive aspects of ototoxicity
Q41817586Immunoassay Analysis of Kanamycin in Serum Using the Tobramycin Kit.
Q42908869Management of Aminoglycosides in the Intensive Care Unit
Q33581183Meropenem. A pharmacoeconomic review of its use in serious infections
Q50530085Monitoring of hearing during treatment of leukaemia with special reference to the use of amikacin.
Q45991071No hearing loss after repeated courses of tobramycin in cystic fibrosis patients.
Q33569075Once-daily aminoglycoside administration in gram-negative sepsis. Economic and practical aspects
Q38239743Once-daily aminoglycoside administration: new strategies for an old drug
Q33928699Once-daily dosing of aminoglycoside antibiotics
Q34521641Ototoxicity induced by gentamicin and furosemide
Q40392377Parenteral aminoglycoside therapy. Selection, administration and monitoring
Q28328534Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection
Q33770259Pharmacokinetics and therapeutic drug monitoring of gentamicin in the elderly
Q40949882Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy
Q33772759Prevention of adverse events in hospitalized patients using an antimicrobial review program
Q92497796Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada
Q38353565Safety and tolerability profile of second-line anti-tuberculosis medications
Q41138730The aminoglycosides
Q38933875The safety and tolerability of the second-line injectable antituberculosis drugs in children.
Q36095859Unique aspects of antimicrobial use in older adults
Q41435517Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations
Q36446781d-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models